SAMDI Tech CEO and CRL Integration Lead, Dr. Emilio Cordova, sat down to answer questions regarding the recent acquisition from Charles River.  

Why did SAMDI Tech choose to be acquired by Charles River?

SAMDI Tech has had a successful partnership with Charles River since 2018. As we looked towards the future of continuing to provide clients with best-in-class assay solutions, joining the Charles River family of companies to offer new ways of accelerating our clients’ drug discovery efforts felt like a natural next step.

How does this acquisition the benefit the life sciences and/or drug discovery industry?

Charles River’s end-to-end portfolio and scientific expertise combined with SAMDI Tech’s innovative technology and expertise in assay solutions has the potential to significantly accelerate timelines and augment drug discovery research. The acquisition now provides both companies’ clients with access to the premier, label-free HTS MS platform and creates a comprehensive, industry-leading library of drug discovery solutions.

What are you most excited about with this acquisition?

Coming together with Charles River strengthens our overall drug discovery capabilities and expands our ability to support our clients in new ways. Combining SAMDI Tech’s cutting-edge label-free technology with Charles River’s premier portfolio further enhances our mission to generate better data faster. With our decade-long drug discovery experience and the successful relationship with Charles River, we trust that this integrated partnership will offer our clients new opportunities to seamlessly move their projects closer to the clinic.

How can we learn more about this new relationship?

In addition to reading more on our websites, we will be exhibiting at the 2023 SLAS conference and exhibition. We are excited to be together in-person to talk with industry colleagues about how we can provide unique solutions to their research projects. You can visit us at either booth #1144 or booth #1156 to meet with our team!